A PD‐L1‐targeting Regulator for Metabolic Reprogramming to Enhance Glutamine Inhibition‐Mediated Synergistic Antitumor Metabolic and Immune Therapy

• Published in: Advanced materials (Weinheim) Vol. 36; no. 6; pp. e2309094 - n/a
• Main Authors: Jin, Xiao‐Kang, Zhang, Shi‐Man, Liang, Jun‐Long, Zhang, Shun‐Kang, Qin, You‐Teng, Huang, Qian‐Xiao, Liu, Chuan‐Jun, Zhang, Xian‐Zheng
• Format: Journal Article
• Language: English
• Published: Germany Wiley Subscription Services, Inc 01.02.2024
• Subjects: B7-H1 Antigen - metabolism; Cell death; Cell Line, Tumor; drug delivering; Glutaminase; Glutamine; Glutamine - antagonists & inhibitors; Glutamine - metabolism; glutamine inhibition; Glycolysis; Homeostasis; Humans; Immune system; Immunosuppressive Agents; Immunotherapy; Metabolic Reprogramming; Metabolism; Metal-organic frameworks; Peptides; self‐amplifying PD‐L1 targeting; tumor immunotherapy; Tumor Microenvironment; Zeolites; self-amplifying PD-L1 targeting; drug delivering; tumor immunotherapy; metabolic reprogramming; glutamine inhibition

Inhibition of glutamine metabolism in tumor cells can cause metabolic compensation‐mediated glycolysis enhancement and PD‐L1 upregulation‐induced immune evasion, significantly limiting the therapeutic efficacy of glutamine inhibitors. Here, inspired by the specific binding of receptor and ligand, a...